Clovis Oncology, Inc. CLVSannounced that the European Commission (“EC”) has conditionally approved its PARP inhibitor, Rubraca (rucaparib) as monotherapy for the treatment of platinum-sensitive and relapsing ovarian cancer patients with BRCA-mutation in third- or later-line setting. The approval was expected as the Committee for Medicinal Products for Human Use (“CHMP”) had issued a positive opinion in March.
Clovis' Rubraca Gets Approval in Europe for Ovarian Cancer
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться